Enovix (NASDAQ:ENVX) Downgraded to “Market Perform” Rating by William Blair

Enovix (NASDAQ:ENVX) was downgraded by investment analysts at William Blair from an “outperform” rating to a “market perform” rating in a report released on Monday.

Other analysts have also issued reports about the company. Canaccord Genuity Group cut their price target on Enovix from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Friday. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of Enovix in a report on Thursday. TD Cowen dropped their target price on Enovix from $7.00 to $5.50 and set a “hold” rating on the stock in a research report on Friday, July 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Enovix in a research note on Wednesday, July 8th. Finally, Wall Street Zen raised Enovix from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Enovix presently has a consensus rating of “Hold” and a consensus price target of $11.86.

Enovix Trading Down 18.1%

Shares of Enovix stock traded down $0.80 during trading hours on Monday, hitting $3.59. The company’s stock had a trading volume of 3,466,584 shares, compared to its average volume of 6,377,921. The company has a market capitalization of $784.03 million, a PE ratio of -4.48 and a beta of 2.32. The company has a debt-to-equity ratio of 2.46, a current ratio of 9.71 and a quick ratio of 9.37. The stock has a 50 day moving average of $5.33 and a 200 day moving average of $5.86. Enovix has a 12 month low of $3.67 and a 12 month high of $14.21.

Enovix (NASDAQ:ENVX) last announced its earnings results on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. Enovix had a negative net margin of 473.89% and a negative return on equity of 64.50%. The firm had revenue of $9.02 million for the quarter, compared to the consensus estimate of $8.43 million. During the same period last year, the company posted ($0.13) EPS. The business’s quarterly revenue was up 20.8% on a year-over-year basis. Enovix has set its Q3 2026 guidance at -0.170–0.130 EPS. Analysts predict that Enovix will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On Enovix

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE acquired a new position in Enovix during the second quarter worth $8,356,000. Jupiter Topco LLC acquired a new stake in Enovix in the second quarter valued at $582,000. Hsbc Holdings PLC bought a new position in shares of Enovix in the 2nd quarter valued at about $261,000. Legal & General Group Plc bought a new position in shares of Enovix in the 2nd quarter valued at about $804,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Enovix during the 2nd quarter worth about $520,000. 50.92% of the stock is owned by institutional investors.

Enovix Company Profile

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.